T. Dwolatzky, V. Whitehead, G. M. Doniger, E. S. Simon, A. Schweiger, D. Jaffe and H. Chertkow, “Validity of a Novel Computerized Cognitive Battery for Mild Cognitive Impairment,” BMC Geriatrics, Vol. 3, No. 1, November 2003, p. 4. http://www.biomedcentral.com/1471-2318/3/4

has been cited by the following article:

• TITLE: Effects of Ginkgo Biloba Special Extract EGb 761® in Very Mild Cognitive Impairment (vMCI)

  AUTHORS: Brigitte Grass-Kapanke, Arija Busmane, Andris Lasmanis, Robert Hoerr, Reiner Kaschel

  KEYWORDS: Ginkgo Biloba, EGb 761®, Mild Cognitive Impairment, Memory, Concentration, Randomised Controlled Trial

  JOURNAL NAME: Neuroscience and Medicine, Vol.2 No.1, March 17, 2011

  ABSTRACT: Objective: To assess effects of EGb 761® on cognition and quality of life in subjects with very mild cognitive impair-ment. Methods: We randomized 300 subjects aged 45 to 65 with cognitive complaints and low functioning (more than one standard deviation below appropriate norm) in at least one cognitive test to double-blind treatment with once daily 240 mg EGb 761® or placebo for 12 weeks. Results: The exploratory intention-to-treat analysis showed significant im-provement (p